Inferior outcomes of liver transplantation for hepatocellular carcinoma during early-COVID-19 pandemic in the United States

Table 2 Pathological characteristics of hepatocellular carcinoma in liver transplant, n (%)

Variable	COVID, n = 518	Pre-COVID, n = 675	Pvalue
Number of tumors
1	229 (44)	333 (49)
2	116 (22)	146 (22)
3	80 (15)	77 (11)
4	36 (6.9)	47 (7.0)
5	22 (4.2)	33 (4.9)
6	31 (6.0)	38 (5.6)
Tumor numbers > 3	89 (17)	118 (17)	0.89
Outside UCSF criteria	131 (25)	178 (26)	0.71
Outside Milan criteria	203 (39)	262 (39)	0.84
Tumor max size, cm median (IQR)	2.80 (1.80, 4.00)	2.90 (1.90, 4.00)	0.92
Worst tumor histology
Complete tumor necrosis	132 (25)	185 (27)	0.5
Moderate differentiated	265 (51)	344 (51)
Poorly differentiated	26 (5.0)	41 (6.1)
Well differentiated	95 (18)	105 (16)
Vascular invasion	6 (1.2)	11 (1.6)	0.019
Macro
Micro	77 (15)	65 (9.6)
None	435 (84)	599 (89)
Lymph node involvement	8 (1.5)	4 (0.6)	0.1
Extra hepatic spread	7 (1.4)	6 (0.9)	0.76
Intrahepatic metastasis	42 (8.1)	36 (5.3)	0.066
Previous treatment for HCC	511 (99)	657 (97)	0.21
High risk features	174 (34)	198 (29)	0.12

COVID: Coronavirus disease; IQR: Interquartile range; UCSF: University of California San Francisco; HCC: Hepatocellular carcinoma.